Clinical  ||| S:0 E:9 ||| JJ
study  ||| S:9 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
Pentraxin  ||| S:18 E:28 ||| NNP
3  ||| S:28 E:30 ||| CD
in  ||| S:30 E:33 ||| IN
diagnosing  ||| S:33 E:44 ||| VBG
the  ||| S:44 E:48 ||| DT
severity  ||| S:48 E:57 ||| NN
and  ||| S:57 E:61 ||| CC
cardiovascular  ||| S:61 E:76 ||| JJ
function  ||| S:76 E:85 ||| NN
of  ||| S:85 E:88 ||| IN
the  ||| S:88 E:92 ||| DT
children  ||| S:92 E:101 ||| NNS
with  ||| S:101 E:106 ||| IN
sepsis  ||| S:106 E:113 ||| VBG
To  ||| S:113 E:116 ||| TO
study  ||| S:116 E:122 ||| VB
the  ||| S:122 E:126 ||| DT
value  ||| S:126 E:132 ||| NN
of  ||| S:132 E:135 ||| IN
Pentraxin  ||| S:135 E:145 ||| NNP
3  ||| S:145 E:147 ||| CD
( ||| S:147 E:148 ||| -LRB-
PTX3 ||| S:148 E:152 ||| NNP
)  ||| S:152 E:154 ||| -RRB-
in  ||| S:154 E:157 ||| IN
diagnosing  ||| S:157 E:168 ||| VBG
the  ||| S:168 E:172 ||| DT
severity  ||| S:172 E:181 ||| NN
and  ||| S:181 E:185 ||| CC
cardiovascular  ||| S:185 E:200 ||| JJ
function  ||| S:200 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
the  ||| S:212 E:216 ||| DT
critically  ||| S:216 E:227 ||| JJ
ill  ||| S:227 E:231 ||| JJ
children ||| S:231 E:239 ||| NNS
.  ||| S:239 E:241 ||| .
Method  ||| S:241 E:248 ||| NN
A  ||| S:248 E:250 ||| DT
total  ||| S:250 E:256 ||| NN
of  ||| S:256 E:259 ||| IN
178  ||| S:259 E:263 ||| CD
patients  ||| S:263 E:272 ||| NNS
who  ||| S:272 E:276 ||| WP
were  ||| S:276 E:281 ||| VBD
older  ||| S:281 E:287 ||| JJR
than  ||| S:287 E:292 ||| IN
28  ||| S:292 E:295 ||| CD
days ||| S:295 E:299 ||| NNS
,  ||| S:299 E:301 ||| ,
with  ||| S:301 E:306 ||| IN
acute  ||| S:306 E:312 ||| JJ
infection  ||| S:312 E:322 ||| NN
of  ||| S:322 E:325 ||| IN
respiratory  ||| S:325 E:337 ||| NN
or  ||| S:337 E:340 ||| CC
neurological  ||| S:340 E:353 ||| JJ
system ||| S:353 E:359 ||| NN
,  ||| S:359 E:361 ||| ,
excluding  ||| S:361 E:371 ||| VBG
chronic  ||| S:371 E:379 ||| NN
or  ||| S:379 E:382 ||| CC
special  ||| S:382 E:390 ||| JJ
disease ||| S:390 E:397 ||| NN
,  ||| S:397 E:399 ||| ,
and  ||| S:399 E:403 ||| CC
admitted  ||| S:403 E:412 ||| VBN
to  ||| S:412 E:415 ||| TO
the  ||| S:415 E:419 ||| DT
pediatric  ||| S:419 E:429 ||| JJ
intensive  ||| S:429 E:439 ||| JJ
care  ||| S:439 E:444 ||| NN
unit  ||| S:444 E:449 ||| NN
( ||| S:449 E:450 ||| -LRB-
PICU ||| S:450 E:454 ||| NNP
)  ||| S:454 E:456 ||| -RRB-
of  ||| S:456 E:459 ||| IN
Hunan  ||| S:459 E:465 ||| NNP
Children ||| S:465 E:473 ||| NNP
's  ||| S:473 E:476 ||| POS
Hospital  ||| S:476 E:485 ||| NN
from  ||| S:485 E:490 ||| IN
October  ||| S:490 E:498 ||| NNP
1 ||| S:498 E:499 ||| CD
,  ||| S:499 E:501 ||| ,
2013  ||| S:501 E:506 ||| CD
to  ||| S:506 E:509 ||| TO
April  ||| S:509 E:515 ||| NNP
30 ||| S:515 E:517 ||| CD
,  ||| S:517 E:519 ||| ,
2014  ||| S:519 E:524 ||| CD
were  ||| S:524 E:529 ||| VBD
enrolled ||| S:529 E:537 ||| CD
,  ||| S:537 E:539 ||| ,
including  ||| S:539 E:549 ||| VBG
102  ||| S:549 E:553 ||| CD
male  ||| S:553 E:558 ||| JJ
cases  ||| S:558 E:564 ||| NNS
and  ||| S:564 E:568 ||| CC
76  ||| S:568 E:571 ||| CD
female  ||| S:571 E:578 ||| JJ
cases ||| S:578 E:583 ||| NNS
.  ||| S:583 E:585 ||| .
The  ||| S:585 E:589 ||| DT
ages  ||| S:589 E:594 ||| NNS
ranged  ||| S:594 E:601 ||| VBD
from  ||| S:601 E:606 ||| IN
1  ||| S:606 E:608 ||| CD
month  ||| S:608 E:614 ||| NN
to  ||| S:614 E:617 ||| TO
13  ||| S:617 E:620 ||| CD
years  ||| S:620 E:626 ||| NNS
and  ||| S:626 E:630 ||| CC
1  ||| S:630 E:632 ||| CD
month ||| S:632 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
78  ||| S:639 E:642 ||| CD
of  ||| S:642 E:645 ||| IN
them  ||| S:645 E:650 ||| PRP
were  ||| S:650 E:655 ||| VBD
less  ||| S:655 E:660 ||| JJR
than  ||| S:660 E:665 ||| IN
1  ||| S:665 E:667 ||| CD
year  ||| S:667 E:672 ||| NN
old  ||| S:672 E:676 ||| JJ
;  ||| S:676 E:678 ||| :
58  ||| S:678 E:681 ||| CD
cases  ||| S:681 E:687 ||| NNS
were  ||| S:687 E:692 ||| VBD
between  ||| S:692 E:700 ||| IN
1  ||| S:700 E:702 ||| CD
to  ||| S:702 E:705 ||| TO
3  ||| S:705 E:707 ||| CD
years  ||| S:707 E:713 ||| NNS
old ||| S:713 E:716 ||| JJ
;  ||| S:716 E:718 ||| :
42  ||| S:718 E:721 ||| CD
cases  ||| S:721 E:727 ||| NNS
were  ||| S:727 E:732 ||| VBD
above  ||| S:732 E:738 ||| IN
3  ||| S:738 E:740 ||| CD
years  ||| S:740 E:746 ||| NNS
old ||| S:746 E:749 ||| JJ
;  ||| S:749 E:751 ||| :
101  ||| S:751 E:755 ||| CD
cases  ||| S:755 E:761 ||| NNS
were  ||| S:761 E:766 ||| VBD
diagnosed  ||| S:766 E:776 ||| VBN
as  ||| S:776 E:779 ||| IN
respiratory  ||| S:779 E:791 ||| JJ
system  ||| S:791 E:798 ||| NN
diseases ||| S:798 E:806 ||| NNS
,  ||| S:806 E:808 ||| ,
77  ||| S:808 E:811 ||| CD
cases  ||| S:811 E:817 ||| NNS
had  ||| S:817 E:821 ||| VBD
nervous  ||| S:821 E:829 ||| JJ
system  ||| S:829 E:836 ||| NN
diseases ||| S:836 E:844 ||| NNS
.  ||| S:844 E:846 ||| .
PTX3  ||| S:846 E:851 ||| NNP
was  ||| S:851 E:855 ||| VBD
detected  ||| S:855 E:864 ||| VBN
with  ||| S:864 E:869 ||| IN
enzyme-linked  ||| S:869 E:883 ||| JJ
immunosorbent  ||| S:883 E:897 ||| JJ
assay  ||| S:897 E:903 ||| NNS
( ||| S:903 E:904 ||| -LRB-
ELISA ||| S:904 E:909 ||| NNP
)  ||| S:909 E:911 ||| -RRB-
within  ||| S:911 E:918 ||| IN
1  ||| S:918 E:920 ||| CD
d  ||| S:920 E:922 ||| NN
after  ||| S:922 E:928 ||| IN
enrollment ||| S:928 E:938 ||| NN
,  ||| S:938 E:940 ||| ,
at  ||| S:940 E:943 ||| IN
3  ||| S:943 E:945 ||| CD
days  ||| S:945 E:950 ||| NNS
and  ||| S:950 E:954 ||| CC
7  ||| S:954 E:956 ||| CD
days ||| S:956 E:960 ||| NNS
,  ||| S:960 E:962 ||| ,
meanwhile ||| S:962 E:971 ||| RB
,  ||| S:971 E:973 ||| ,
troponin ||| S:973 E:981 ||| NN
,  ||| S:981 E:983 ||| ,
myocardial  ||| S:983 E:994 ||| JJ
enzyme ||| S:994 E:1000 ||| NN
,  ||| S:1000 E:1002 ||| ,
brain-type  ||| S:1002 E:1013 ||| FW
natriuretic  ||| S:1013 E:1025 ||| FW
peptide  ||| S:1025 E:1033 ||| FW
( ||| S:1033 E:1034 ||| -LRB-
BNP ||| S:1034 E:1037 ||| NNP
) ||| S:1037 E:1038 ||| -RRB-
,  ||| S:1038 E:1040 ||| ,
C-reactive  ||| S:1040 E:1051 ||| JJ
protein  ||| S:1051 E:1059 ||| NN
( ||| S:1059 E:1060 ||| -LRB-
CRP ||| S:1060 E:1063 ||| NNP
) ||| S:1063 E:1064 ||| -RRB-
,  ||| S:1064 E:1066 ||| ,
plasma  ||| S:1066 E:1073 ||| FW
calcitonin  ||| S:1073 E:1084 ||| FW
( ||| S:1084 E:1085 ||| -LRB-
PCT ||| S:1085 E:1088 ||| NNP
)  ||| S:1088 E:1090 ||| -RRB-
and  ||| S:1090 E:1094 ||| CC
WBC  ||| S:1094 E:1098 ||| NNP
etc ||| S:1098 E:1101 ||| FW
.  ||| S:1101 E:1103 ||| .
Were  ||| S:1103 E:1108 ||| VBD
measured ||| S:1108 E:1116 ||| VBN
.  ||| S:1116 E:1118 ||| .
According  ||| S:1118 E:1128 ||| VBG
to  ||| S:1128 E:1131 ||| TO
the  ||| S:1131 E:1135 ||| DT
plasma  ||| S:1135 E:1142 ||| JJ
PTX3  ||| S:1142 E:1147 ||| CD
value  ||| S:1147 E:1153 ||| NN
which  ||| S:1153 E:1159 ||| WDT
were  ||| S:1159 E:1164 ||| VBD
measured  ||| S:1164 E:1173 ||| VBN
within  ||| S:1173 E:1180 ||| IN
24  ||| S:1180 E:1183 ||| CD
h  ||| S:1183 E:1185 ||| NN
after  ||| S:1185 E:1191 ||| IN
enrollment  ||| S:1191 E:1202 ||| VBG
the  ||| S:1202 E:1206 ||| DT
patients  ||| S:1206 E:1215 ||| NNS
were  ||| S:1215 E:1220 ||| VBD
divided  ||| S:1220 E:1228 ||| VBN
into  ||| S:1228 E:1233 ||| IN
three  ||| S:1233 E:1239 ||| CD
groups ||| S:1239 E:1245 ||| NNS
:  ||| S:1245 E:1247 ||| :
mildly  ||| S:1247 E:1254 ||| RB
elevated  ||| S:1254 E:1263 ||| JJ
group  ||| S:1263 E:1269 ||| NN
(  ||| S:1269 E:1270 ||| -LRB-
< ||| S:1270 E:1272 ||| SYM
44  ||| S:1272 E:1275 ||| CD
µg ||| S:1275 E:1277 ||| CD
/ ||| S:1277 E:1278 ||| CD
L ||| S:1278 E:1279 ||| NNP
)  ||| S:1279 E:1281 ||| -RRB-
41  ||| S:1281 E:1284 ||| CD
cases ||| S:1284 E:1289 ||| NNS
;  ||| S:1289 E:1291 ||| :
moderately  ||| S:1291 E:1302 ||| RB
elevated  ||| S:1302 E:1311 ||| JJ
group  ||| S:1311 E:1317 ||| NN
( ||| S:1317 E:1318 ||| -LRB-
44  ||| S:1318 E:1321 ||| CD
-  ||| S:1321 E:1323 ||| :
< ||| S:1323 E:1325 ||| SYM
132  ||| S:1325 E:1329 ||| CD
µg ||| S:1329 E:1331 ||| CD
/ ||| S:1331 E:1332 ||| CD
L ||| S:1332 E:1333 ||| NNP
)  ||| S:1333 E:1335 ||| -RRB-
in  ||| S:1335 E:1338 ||| IN
66  ||| S:1338 E:1341 ||| CD
cases ||| S:1341 E:1346 ||| NNS
;  ||| S:1346 E:1348 ||| :
severely  ||| S:1348 E:1357 ||| RB
elevated  ||| S:1357 E:1366 ||| JJ
group  ||| S:1366 E:1372 ||| NN
71  ||| S:1372 E:1375 ||| CD
cases  ||| S:1375 E:1381 ||| NNS
( ||| S:1381 E:1382 ||| -LRB-
132  ||| S:1382 E:1386 ||| CD
µg ||| S:1386 E:1388 ||| CD
/ ||| S:1388 E:1389 ||| CD
L  ||| S:1389 E:1391 ||| NNP
or  ||| S:1391 E:1394 ||| CC
higher ||| S:1394 E:1400 ||| JJR
) ||| S:1400 E:1401 ||| -RRB-
.  ||| S:1401 E:1403 ||| .
Those  ||| S:1403 E:1409 ||| DT
178  ||| S:1409 E:1413 ||| CD
patients  ||| S:1413 E:1422 ||| NNS
were  ||| S:1422 E:1427 ||| VBD
divided  ||| S:1427 E:1435 ||| VBN
into  ||| S:1435 E:1440 ||| IN
3  ||| S:1440 E:1442 ||| CD
groups  ||| S:1442 E:1449 ||| NNS
according  ||| S:1449 E:1459 ||| VBG
to  ||| S:1459 E:1462 ||| TO
the  ||| S:1462 E:1466 ||| DT
degree  ||| S:1466 E:1473 ||| NN
of  ||| S:1473 E:1476 ||| IN
infection ||| S:1476 E:1485 ||| NN
:  ||| S:1485 E:1487 ||| :
non-sepsis  ||| S:1487 E:1498 ||| JJ
group  ||| S:1498 E:1504 ||| NN
( ||| S:1504 E:1505 ||| -LRB-
78  ||| S:1505 E:1508 ||| CD
cases ||| S:1508 E:1513 ||| NNS
) ||| S:1513 E:1514 ||| -RRB-
,  ||| S:1514 E:1516 ||| ,
sepsis  ||| S:1516 E:1523 ||| JJ
group  ||| S:1523 E:1529 ||| NN
( ||| S:1529 E:1530 ||| -LRB-
70  ||| S:1530 E:1533 ||| CD
cases ||| S:1533 E:1538 ||| NNS
) ||| S:1538 E:1539 ||| -RRB-
,  ||| S:1539 E:1541 ||| ,
severe  ||| S:1541 E:1548 ||| JJ
sepsis  ||| S:1548 E:1555 ||| JJ
group  ||| S:1555 E:1561 ||| NN
( ||| S:1561 E:1562 ||| -LRB-
30  ||| S:1562 E:1565 ||| CD
cases ||| S:1565 E:1570 ||| NNS
) ||| S:1570 E:1571 ||| -RRB-
,  ||| S:1571 E:1573 ||| ,
and  ||| S:1573 E:1577 ||| CC
in  ||| S:1577 E:1580 ||| IN
each  ||| S:1580 E:1585 ||| DT
group ||| S:1585 E:1590 ||| NN
,  ||| S:1590 E:1592 ||| ,
those  ||| S:1592 E:1598 ||| DT
with  ||| S:1598 E:1603 ||| IN
heart  ||| S:1603 E:1609 ||| NN
failure  ||| S:1609 E:1617 ||| NN
were  ||| S:1617 E:1622 ||| VBD
respectively  ||| S:1622 E:1635 ||| RB
19  ||| S:1635 E:1638 ||| CD
cases ||| S:1638 E:1643 ||| NNS
,  ||| S:1643 E:1645 ||| ,
28  ||| S:1645 E:1648 ||| CD
cases ||| S:1648 E:1653 ||| NNS
,  ||| S:1653 E:1655 ||| ,
17  ||| S:1655 E:1658 ||| CD
cases ||| S:1658 E:1663 ||| NNS
.  ||| S:1663 E:1665 ||| .
Analysis  ||| S:1665 E:1674 ||| NN
of  ||| S:1674 E:1677 ||| IN
the  ||| S:1677 E:1681 ||| DT
plasma  ||| S:1681 E:1688 ||| JJ
PTX3  ||| S:1688 E:1693 ||| CD
expression  ||| S:1693 E:1704 ||| NN
changes  ||| S:1704 E:1712 ||| NNS
in  ||| S:1712 E:1715 ||| IN
different  ||| S:1715 E:1725 ||| JJ
clinical  ||| S:1725 E:1734 ||| JJ
manifestations ||| S:1734 E:1748 ||| NNS
,  ||| S:1748 E:1750 ||| ,
different  ||| S:1750 E:1760 ||| JJ
condition ||| S:1760 E:1769 ||| NN
,  ||| S:1769 E:1771 ||| ,
different  ||| S:1771 E:1781 ||| JJ
degrees  ||| S:1781 E:1789 ||| NNS
of  ||| S:1789 E:1792 ||| IN
organ  ||| S:1792 E:1798 ||| JJ
damages  ||| S:1798 E:1806 ||| NNS
and  ||| S:1806 E:1810 ||| CC
prognosis  ||| S:1810 E:1820 ||| NN
for  ||| S:1820 E:1824 ||| IN
the  ||| S:1824 E:1828 ||| DT
patient ||| S:1828 E:1835 ||| NN
.  ||| S:1835 E:1837 ||| .
The  ||| S:1837 E:1841 ||| DT
continuous  ||| S:1841 E:1852 ||| JJ
variables  ||| S:1852 E:1862 ||| NNS
were  ||| S:1862 E:1867 ||| VBD
analyzed  ||| S:1867 E:1876 ||| VBN
with  ||| S:1876 E:1881 ||| IN
t-test ||| S:1881 E:1887 ||| NNP
,  ||| S:1887 E:1889 ||| ,
F-test ||| S:1889 E:1895 ||| NNP
,  ||| S:1895 E:1897 ||| ,
H-test ||| S:1897 E:1903 ||| NNP
,  ||| S:1903 E:1905 ||| ,
the  ||| S:1905 E:1909 ||| DT
categorical  ||| S:1909 E:1921 ||| JJ
variables  ||| S:1921 E:1931 ||| NNS
were  ||| S:1931 E:1936 ||| VBD
analyzed  ||| S:1936 E:1945 ||| VBN
with  ||| S:1945 E:1950 ||| IN
Chi-square  ||| S:1950 E:1961 ||| JJ
test ||| S:1961 E:1965 ||| NN
,  ||| S:1965 E:1967 ||| ,
and  ||| S:1967 E:1971 ||| CC
the  ||| S:1971 E:1975 ||| DT
correlation  ||| S:1975 E:1987 ||| JJ
analysis  ||| S:1987 E:1996 ||| NN
was  ||| S:1996 E:2000 ||| VBD
performed  ||| S:2000 E:2010 ||| VBN
to  ||| S:2010 E:2013 ||| TO
calculate  ||| S:2013 E:2023 ||| VB
Pearson  ||| S:2023 E:2031 ||| NNP
coefficients ||| S:2031 E:2043 ||| NN
.  ||| S:2043 E:2045 ||| .
The  ||| S:2045 E:2049 ||| DT
PTX3  ||| S:2049 E:2054 ||| JJ
value  ||| S:2054 E:2060 ||| NN
measured  ||| S:2060 E:2069 ||| VBN
within  ||| S:2069 E:2076 ||| IN
24  ||| S:2076 E:2079 ||| CD
h  ||| S:2079 E:2081 ||| NN
after  ||| S:2081 E:2087 ||| IN
enrollment  ||| S:2087 E:2098 ||| NN
increased  ||| S:2098 E:2108 ||| VBN
with  ||| S:2108 E:2113 ||| IN
the  ||| S:2113 E:2117 ||| DT
degree  ||| S:2117 E:2124 ||| NN
of  ||| S:2124 E:2127 ||| IN
infection  ||| S:2127 E:2137 ||| NN
( ||| S:2137 E:2138 ||| -LRB-
50.  ||| S:2138 E:2142 ||| CD
4 ||| S:2142 E:2143 ||| CD
( ||| S:2143 E:2144 ||| -LRB-
35.  ||| S:2144 E:2148 ||| CD
2,70.  ||| S:2148 E:2154 ||| CD
4 ||| S:2154 E:2155 ||| CD
)  ||| S:2155 E:2157 ||| -RRB-
µg ||| S:2157 E:2159 ||| FW
/ ||| S:2159 E:2160 ||| FW
L ||| S:2160 E:2161 ||| NNP
;  ||| S:2161 E:2163 ||| :
175.  ||| S:2163 E:2168 ||| CD
8  ||| S:2168 E:2170 ||| CD
( ||| S:2170 E:2171 ||| -LRB-
99.  ||| S:2171 E:2175 ||| CD
6 ||| S:2175 E:2176 ||| CD
,  ||| S:2176 E:2178 ||| ,
309.  ||| S:2178 E:2183 ||| CD
9 ||| S:2183 E:2184 ||| CD
)  ||| S:2184 E:2186 ||| -RRB-
µg ||| S:2186 E:2188 ||| FW
/ ||| S:2188 E:2189 ||| FW
L ||| S:2189 E:2190 ||| NNP
; ||| S:2190 E:2191 ||| :
419.  ||| S:2191 E:2196 ||| CD
9  ||| S:2196 E:2198 ||| CD
( ||| S:2198 E:2199 ||| -LRB-
168.  ||| S:2199 E:2204 ||| CD
3 ||| S:2204 E:2205 ||| CD
,  ||| S:2205 E:2207 ||| ,
468.  ||| S:2207 E:2212 ||| CD
6 ||| S:2212 E:2213 ||| CD
)  ||| S:2213 E:2215 ||| -RRB-
µg ||| S:2215 E:2217 ||| FW
/ ||| S:2217 E:2218 ||| FW
L ||| S:2218 E:2219 ||| NNP
;  ||| S:2219 E:2221 ||| :
H  ||| S:2221 E:2223 ||| NNP
=  ||| S:2223 E:2225 ||| SYM
88.  ||| S:2225 E:2229 ||| CD
345 ||| S:2229 E:2232 ||| CD
,  ||| S:2232 E:2234 ||| ,
P  ||| S:2234 E:2236 ||| NN
=  ||| S:2236 E:2238 ||| SYM
0.  ||| S:2238 E:2241 ||| CD
000 ||| S:2241 E:2244 ||| CD
) ||| S:2244 E:2245 ||| -RRB-
.  ||| S:2245 E:2247 ||| .
PTX3  ||| S:2247 E:2252 ||| NNP
level  ||| S:2252 E:2258 ||| NN
gradually  ||| S:2258 E:2268 ||| RB
declined ||| S:2268 E:2276 ||| VBD
,  ||| S:2276 E:2278 ||| ,
while  ||| S:2278 E:2284 ||| IN
in  ||| S:2284 E:2287 ||| IN
severe  ||| S:2287 E:2294 ||| JJ
sepsis  ||| S:2294 E:2301 ||| JJ
group  ||| S:2301 E:2307 ||| NN
decreased  ||| S:2307 E:2317 ||| VBD
slowly  ||| S:2317 E:2324 ||| RB
( ||| S:2324 E:2325 ||| -LRB-
P  ||| S:2325 E:2327 ||| NNP
< ||| S:2327 E:2328 ||| SYM
0.  ||| S:2328 E:2331 ||| CD
05 ||| S:2331 E:2333 ||| CD
) ||| S:2333 E:2334 ||| -RRB-
;  ||| S:2334 E:2336 ||| :
the  ||| S:2336 E:2340 ||| DT
area  ||| S:2340 E:2345 ||| NN
under  ||| S:2345 E:2351 ||| IN
the  ||| S:2351 E:2355 ||| DT
ROC  ||| S:2355 E:2359 ||| NNP
curve  ||| S:2359 E:2365 ||| NN
of  ||| S:2365 E:2368 ||| IN
Plasma  ||| S:2368 E:2375 ||| NNP
PTX3  ||| S:2375 E:2380 ||| NNP
was  ||| S:2380 E:2384 ||| VBD
larger  ||| S:2384 E:2391 ||| JJR
than  ||| S:2391 E:2396 ||| IN
that  ||| S:2396 E:2401 ||| DT
of  ||| S:2401 E:2404 ||| IN
other  ||| S:2404 E:2410 ||| JJ
inflammatory  ||| S:2410 E:2423 ||| JJ
markers  ||| S:2423 E:2431 ||| JJ
such  ||| S:2431 E:2436 ||| JJ
as  ||| S:2436 E:2439 ||| IN
CRP  ||| S:2439 E:2443 ||| NNP
and  ||| S:2443 E:2447 ||| CC
PCT ||| S:2447 E:2450 ||| NNP
,  ||| S:2450 E:2452 ||| ,
white  ||| S:2452 E:2458 ||| JJ
blood  ||| S:2458 E:2464 ||| NN
cells  ||| S:2464 E:2470 ||| NNS
and  ||| S:2470 E:2474 ||| CC
neutrophils  ||| S:2474 E:2486 ||| NN
in  ||| S:2486 E:2489 ||| IN
the  ||| S:2489 E:2493 ||| DT
diagnosis  ||| S:2493 E:2503 ||| NN
of  ||| S:2503 E:2506 ||| IN
sepsis ||| S:2506 E:2512 ||| NN
;  ||| S:2512 E:2514 ||| :
while  ||| S:2514 E:2520 ||| IN
the  ||| S:2520 E:2524 ||| DT
former  ||| S:2524 E:2531 ||| JJ
three  ||| S:2531 E:2537 ||| CD
are  ||| S:2537 E:2541 ||| VBP
PTX3 ||| S:2541 E:2545 ||| RB
,  ||| S:2545 E:2547 ||| ,
PCT  ||| S:2547 E:2551 ||| NNP
and  ||| S:2551 E:2555 ||| CC
CRP  ||| S:2555 E:2559 ||| NNP
( ||| S:2559 E:2560 ||| -LRB-
the  ||| S:2560 E:2564 ||| DT
sensitivity  ||| S:2564 E:2576 ||| NN
and  ||| S:2576 E:2580 ||| CC
specificity  ||| S:2580 E:2592 ||| VBP
respectively  ||| S:2592 E:2605 ||| RB
were  ||| S:2605 E:2610 ||| VBD
0.  ||| S:2610 E:2613 ||| CD
77 ||| S:2613 E:2615 ||| CD
,  ||| S:2615 E:2617 ||| ,
0.  ||| S:2617 E:2620 ||| CD
68 ||| S:2620 E:2622 ||| CD
;  ||| S:2622 E:2624 ||| :
0.  ||| S:2624 E:2627 ||| CD
66 ||| S:2627 E:2629 ||| CD
,  ||| S:2629 E:2631 ||| ,
0.  ||| S:2631 E:2634 ||| CD
6 ||| S:2634 E:2635 ||| CD
;  ||| S:2635 E:2637 ||| :
0.  ||| S:2637 E:2640 ||| CD
47 ||| S:2640 E:2642 ||| CD
,  ||| S:2642 E:2644 ||| ,
0.  ||| S:2644 E:2647 ||| CD
55 ||| S:2647 E:2649 ||| CD
) ||| S:2649 E:2650 ||| -RRB-
;  ||| S:2650 E:2652 ||| :
the  ||| S:2652 E:2656 ||| DT
PTX3  ||| S:2656 E:2661 ||| JJ
value  ||| S:2661 E:2667 ||| NN
of  ||| S:2667 E:2670 ||| IN
the  ||| S:2670 E:2674 ||| DT
severely  ||| S:2674 E:2683 ||| RB
elevated  ||| S:2683 E:2692 ||| JJ
group  ||| S:2692 E:2698 ||| NN
was  ||| S:2698 E:2702 ||| VBD
significantly  ||| S:2702 E:2716 ||| RB
higher  ||| S:2716 E:2723 ||| JJR
than  ||| S:2723 E:2728 ||| IN
those  ||| S:2728 E:2734 ||| DT
of  ||| S:2734 E:2737 ||| IN
the  ||| S:2737 E:2741 ||| DT
mildly  ||| S:2741 E:2748 ||| NN
and  ||| S:2748 E:2752 ||| CC
moderately  ||| S:2752 E:2763 ||| RB
elevated  ||| S:2763 E:2772 ||| JJ
groups  ||| S:2772 E:2779 ||| NNS
( ||| S:2779 E:2780 ||| -LRB-
P  ||| S:2780 E:2782 ||| NNP
< ||| S:2782 E:2783 ||| SYM
0.  ||| S:2783 E:2786 ||| CD
05 ||| S:2786 E:2788 ||| CD
) ||| S:2788 E:2789 ||| -RRB-
.  ||| S:2789 E:2791 ||| .
The  ||| S:2791 E:2795 ||| DT
proportion  ||| S:2795 E:2806 ||| NN
of  ||| S:2806 E:2809 ||| IN
having  ||| S:2809 E:2816 ||| VBG
3  ||| S:2816 E:2818 ||| CD
or  ||| S:2818 E:2821 ||| CC
more  ||| S:2821 E:2826 ||| RBR
organs  ||| S:2826 E:2833 ||| JJ
failure  ||| S:2833 E:2841 ||| NN
increased  ||| S:2841 E:2851 ||| VBN
as  ||| S:2851 E:2854 ||| IN
the  ||| S:2854 E:2858 ||| DT
PTX3  ||| S:2858 E:2863 ||| NN
rising  ||| S:2863 E:2870 ||| VBG
among  ||| S:2870 E:2876 ||| IN
the  ||| S:2876 E:2880 ||| DT
groups  ||| S:2880 E:2887 ||| NNS
of  ||| S:2887 E:2890 ||| IN
mildly  ||| S:2890 E:2897 ||| RB
elevated  ||| S:2897 E:2906 ||| JJ
group ||| S:2906 E:2911 ||| NN
,  ||| S:2911 E:2913 ||| ,
moderately  ||| S:2913 E:2924 ||| RB
elevated  ||| S:2924 E:2933 ||| JJ
group  ||| S:2933 E:2939 ||| NN
and  ||| S:2939 E:2943 ||| CC
severely  ||| S:2943 E:2952 ||| RB
elevated  ||| S:2952 E:2961 ||| JJ
group  ||| S:2961 E:2967 ||| NN
( ||| S:2967 E:2968 ||| -LRB-
1 ||| S:2968 E:2969 ||| CD
( ||| S:2969 E:2970 ||| -LRB-
2.  ||| S:2970 E:2973 ||| CD
4 ||| S:2973 E:2974 ||| CD
% ||| S:2974 E:2975 ||| NN
) ||| S:2975 E:2976 ||| -RRB-
,  ||| S:2976 E:2978 ||| ,
4 ||| S:2978 E:2979 ||| CD
( ||| S:2979 E:2980 ||| -LRB-
6.  ||| S:2980 E:2983 ||| CD
1 ||| S:2983 E:2984 ||| CD
% ||| S:2984 E:2985 ||| NN
) ||| S:2985 E:2986 ||| -RRB-
,  ||| S:2986 E:2988 ||| ,
14 ||| S:2988 E:2990 ||| CD
( ||| S:2990 E:2991 ||| -LRB-
19.  ||| S:2991 E:2995 ||| CD
7 ||| S:2995 E:2996 ||| CD
% ||| S:2996 E:2997 ||| NN
)  ||| S:2997 E:2999 ||| -RRB-
χ2  ||| S:2999 E:3002 ||| CD
=16.  ||| S:3002 E:3007 ||| CD
16 ||| S:3007 E:3009 ||| CD
, ||| S:3009 E:3010 ||| ,
P  ||| S:3010 E:3012 ||| NN
=  ||| S:3012 E:3014 ||| SYM
0.  ||| S:3014 E:3017 ||| CD
000 ||| S:3017 E:3020 ||| CD
) ||| S:3020 E:3021 ||| -RRB-
;  ||| S:3021 E:3023 ||| :
and  ||| S:3023 E:3027 ||| CC
in  ||| S:3027 E:3030 ||| IN
each  ||| S:3030 E:3035 ||| DT
group ||| S:3035 E:3040 ||| NN
,  ||| S:3040 E:3042 ||| ,
the  ||| S:3042 E:3046 ||| DT
proportion  ||| S:3046 E:3057 ||| NN
of  ||| S:3057 E:3060 ||| IN
having  ||| S:3060 E:3067 ||| VBG
good  ||| S:3067 E:3072 ||| JJ
and  ||| S:3072 E:3076 ||| CC
poor  ||| S:3076 E:3081 ||| JJ
prognosis  ||| S:3081 E:3091 ||| NN
for  ||| S:3091 E:3095 ||| IN
these  ||| S:3095 E:3101 ||| DT
three  ||| S:3101 E:3107 ||| CD
groups  ||| S:3107 E:3114 ||| NNS
were  ||| S:3114 E:3119 ||| VBD
different  ||| S:3119 E:3129 ||| JJ
( ||| S:3129 E:3130 ||| -LRB-
33  ||| S:3130 E:3133 ||| CD
( ||| S:3133 E:3134 ||| -LRB-
80.5 ||| S:3134 E:3138 ||| NNP
% ||| S:3138 E:3139 ||| NN
)  ||| S:3139 E:3141 ||| -RRB-
and  ||| S:3141 E:3145 ||| CC
8  ||| S:3145 E:3147 ||| CD
( ||| S:3147 E:3148 ||| -LRB-
19.  ||| S:3148 E:3152 ||| CD
5 ||| S:3152 E:3153 ||| CD
% ||| S:3153 E:3154 ||| NN
) ||| S:3154 E:3155 ||| -RRB-
,  ||| S:3155 E:3157 ||| ,
35  ||| S:3157 E:3160 ||| CD
( ||| S:3160 E:3161 ||| -LRB-
53 ||| S:3161 E:3163 ||| CD
% ||| S:3163 E:3164 ||| NN
)  ||| S:3164 E:3166 ||| -RRB-
and  ||| S:3166 E:3170 ||| CC
31  ||| S:3170 E:3173 ||| CD
( ||| S:3173 E:3174 ||| -LRB-
47 ||| S:3174 E:3176 ||| CD
% ||| S:3176 E:3177 ||| NN
) ||| S:3177 E:3178 ||| -RRB-
,  ||| S:3178 E:3180 ||| ,
28  ||| S:3180 E:3183 ||| CD
( ||| S:3183 E:3184 ||| -LRB-
39.4 ||| S:3184 E:3188 ||| CD
% ||| S:3188 E:3189 ||| NN
)  ||| S:3189 E:3191 ||| -RRB-
and  ||| S:3191 E:3195 ||| CC
43  ||| S:3195 E:3198 ||| CD
( ||| S:3198 E:3199 ||| -LRB-
60.6 ||| S:3199 E:3203 ||| CD
% ||| S:3203 E:3204 ||| NN
) ||| S:3204 E:3205 ||| -RRB-
,  ||| S:3205 E:3207 ||| ,
χ  ||| S:3207 E:3209 ||| VBG
=  ||| S:3209 E:3211 ||| SYM
17.  ||| S:3211 E:3215 ||| CD
663 ||| S:3215 E:3218 ||| CD
,  ||| S:3218 E:3220 ||| ,
P  ||| S:3220 E:3222 ||| NN
=  ||| S:3222 E:3224 ||| SYM
0.  ||| S:3224 E:3227 ||| CD
000 ||| S:3227 E:3230 ||| CD
) ||| S:3230 E:3231 ||| -RRB-
.  ||| S:3231 E:3233 ||| .
The  ||| S:3233 E:3237 ||| DT
K-M  ||| S:3237 E:3241 ||| JJ
curve  ||| S:3241 E:3247 ||| NN
for  ||| S:3247 E:3251 ||| IN
these  ||| S:3251 E:3257 ||| DT
three  ||| S:3257 E:3263 ||| CD
groups  ||| S:3263 E:3270 ||| NNS
had  ||| S:3270 E:3274 ||| VBD
statistically  ||| S:3274 E:3288 ||| RB
significant  ||| S:3288 E:3300 ||| JJ
difference  ||| S:3300 E:3311 ||| NN
( ||| S:3311 E:3312 ||| -LRB-
χ2  ||| S:3312 E:3315 ||| CD
=  ||| S:3315 E:3317 ||| SYM
7.  ||| S:3317 E:3320 ||| CD
086 ||| S:3320 E:3323 ||| CD
,  ||| S:3323 E:3325 ||| ,
P  ||| S:3325 E:3327 ||| NN
=  ||| S:3327 E:3329 ||| SYM
0.  ||| S:3329 E:3332 ||| CD
029 ||| S:3332 E:3335 ||| CD
) ||| S:3335 E:3336 ||| -RRB-
.  ||| S:3336 E:3338 ||| .
Those  ||| S:3338 E:3344 ||| DT
with  ||| S:3344 E:3349 ||| IN
heart  ||| S:3349 E:3355 ||| NN
failure  ||| S:3355 E:3363 ||| NN
had  ||| S:3363 E:3367 ||| VBD
higher  ||| S:3367 E:3374 ||| JJR
PTX3  ||| S:3374 E:3379 ||| NN
value  ||| S:3379 E:3385 ||| NN
than  ||| S:3385 E:3390 ||| IN
those  ||| S:3390 E:3396 ||| DT
in  ||| S:3396 E:3399 ||| IN
non-heart  ||| S:3399 E:3409 ||| JJ
failure  ||| S:3409 E:3417 ||| NN
at  ||| S:3417 E:3420 ||| IN
the  ||| S:3420 E:3424 ||| DT
same  ||| S:3424 E:3429 ||| JJ
degree  ||| S:3429 E:3436 ||| NN
of  ||| S:3436 E:3439 ||| IN
infection ||| S:3439 E:3448 ||| NN
.  ||| S:3448 E:3450 ||| .
PTX3  ||| S:3450 E:3455 ||| NNP
value  ||| S:3455 E:3461 ||| NN
increased  ||| S:3461 E:3471 ||| VBN
with  ||| S:3471 E:3476 ||| IN
myocardial  ||| S:3476 E:3487 ||| JJ
enzyme  ||| S:3487 E:3494 ||| NNS
( ||| S:3494 E:3495 ||| -LRB-
troponin ||| S:3495 E:3503 ||| UH
,  ||| S:3503 E:3505 ||| ,
creatine  ||| S:3505 E:3514 ||| FW
kinase  ||| S:3514 E:3521 ||| FW
isoenzyme ||| S:3521 E:3530 ||| FW
,  ||| S:3530 E:3532 ||| ,
BNP ||| S:3532 E:3535 ||| NNP
)  ||| S:3535 E:3537 ||| -RRB-
levels ||| S:3537 E:3543 ||| NNS
.  ||| S:3543 E:3545 ||| .
In  ||| S:3545 E:3548 ||| IN
the  ||| S:3548 E:3552 ||| DT
diagnosis  ||| S:3552 E:3562 ||| NN
of  ||| S:3562 E:3565 ||| IN
heart  ||| S:3565 E:3571 ||| NN
failure ||| S:3571 E:3578 ||| NN
,  ||| S:3578 E:3580 ||| ,
the  ||| S:3580 E:3584 ||| DT
area  ||| S:3584 E:3589 ||| NN
under  ||| S:3589 E:3595 ||| IN
the  ||| S:3595 E:3599 ||| DT
ROC  ||| S:3599 E:3603 ||| NNP
curve  ||| S:3603 E:3609 ||| NN
were  ||| S:3609 E:3614 ||| VBD
respectively  ||| S:3614 E:3627 ||| RB
PTX3  ||| S:3627 E:3632 ||| CD
0.  ||| S:3632 E:3635 ||| CD
824 ||| S:3635 E:3638 ||| CD
;  ||| S:3638 E:3640 ||| :
BNP  ||| S:3640 E:3644 ||| NNP
0.  ||| S:3644 E:3647 ||| CD
772 ||| S:3647 E:3650 ||| CD
;  ||| S:3650 E:3652 ||| :
CM-KB  ||| S:3652 E:3658 ||| JJ
0.  ||| S:3658 E:3661 ||| CD
643 ||| S:3661 E:3664 ||| CD
;  ||| S:3664 E:3666 ||| :
CNTIO.  ||| S:3666 E:3673 ||| CD
671 ||| S:3673 E:3676 ||| CD
,  ||| S:3676 E:3678 ||| ,
the  ||| S:3678 E:3682 ||| DT
sensitivity  ||| S:3682 E:3694 ||| NN
and  ||| S:3694 E:3698 ||| CC
specificity  ||| S:3698 E:3710 ||| NN
were  ||| S:3710 E:3715 ||| VBD
PTX3  ||| S:3715 E:3720 ||| CD
0.  ||| S:3720 E:3723 ||| CD
8 ||| S:3723 E:3724 ||| CD
,  ||| S:3724 E:3726 ||| ,
0.  ||| S:3726 E:3729 ||| CD
58 ||| S:3729 E:3731 ||| CD
;  ||| S:3731 E:3733 ||| :
CK-MB  ||| S:3733 E:3739 ||| JJ
0.  ||| S:3739 E:3742 ||| CD
56,0.  ||| S:3742 E:3748 ||| CD
79 ||| S:3748 E:3750 ||| CD
;  ||| S:3750 E:3752 ||| :
CTNI  ||| S:3752 E:3757 ||| NNP
0.  ||| S:3757 E:3760 ||| CD
60,0.  ||| S:3760 E:3766 ||| CD
69 ||| S:3766 E:3768 ||| CD
;  ||| S:3768 E:3770 ||| :
BNP  ||| S:3770 E:3774 ||| NNP
0.  ||| S:3774 E:3777 ||| CD
73 ||| S:3777 E:3779 ||| CD
,  ||| S:3779 E:3781 ||| ,
0.  ||| S:3781 E:3784 ||| CD
58 ||| S:3784 E:3786 ||| CD
.  ||| S:3786 E:3788 ||| .
In  ||| S:3788 E:3791 ||| IN
terms  ||| S:3791 E:3797 ||| NNS
of  ||| S:3797 E:3800 ||| IN
predicting  ||| S:3800 E:3811 ||| VBG
the  ||| S:3811 E:3815 ||| DT
prognosis  ||| S:3815 E:3825 ||| NN
of  ||| S:3825 E:3828 ||| IN
sepsis  ||| S:3828 E:3835 ||| NN
with  ||| S:3835 E:3840 ||| IN
heart  ||| S:3840 E:3846 ||| NN
failure  ||| S:3846 E:3854 ||| NN
complications ||| S:3854 E:3867 ||| NNS
,  ||| S:3867 E:3869 ||| ,
the  ||| S:3869 E:3873 ||| DT
PTX3  ||| S:3873 E:3878 ||| JJ
value ||| S:3878 E:3883 ||| NN
's  ||| S:3883 E:3886 ||| POS
area  ||| S:3886 E:3891 ||| NN
under  ||| S:3891 E:3897 ||| IN
ROC  ||| S:3897 E:3901 ||| NNP
curve  ||| S:3901 E:3907 ||| NN
was  ||| S:3907 E:3911 ||| VBD
larger  ||| S:3911 E:3918 ||| JJR
than  ||| S:3918 E:3923 ||| IN
that  ||| S:3923 E:3928 ||| DT
of  ||| S:3928 E:3931 ||| IN
BNP  ||| S:3931 E:3935 ||| NNP
( ||| S:3935 E:3936 ||| -LRB-
respectively  ||| S:3936 E:3949 ||| RB
0.  ||| S:3949 E:3952 ||| CD
844 ||| S:3952 E:3955 ||| CD
,  ||| S:3955 E:3957 ||| ,
0.  ||| S:3957 E:3960 ||| CD
472 ||| S:3960 E:3963 ||| CD
) ||| S:3963 E:3964 ||| -RRB-
.  ||| S:3964 E:3966 ||| .
The  ||| S:3966 E:3970 ||| DT
PTX3  ||| S:3970 E:3975 ||| NNP
is  ||| S:3975 E:3978 ||| VBZ
an  ||| S:3978 E:3981 ||| DT
objective  ||| S:3981 E:3991 ||| JJ
biochemical  ||| S:3991 E:4003 ||| JJ
marker  ||| S:4003 E:4010 ||| NN
in  ||| S:4010 E:4013 ||| IN
diagnosis  ||| S:4013 E:4023 ||| NN
of  ||| S:4023 E:4026 ||| IN
sepsis ||| S:4026 E:4032 ||| NN
;  ||| S:4032 E:4034 ||| :
it  ||| S:4034 E:4037 ||| PRP
is  ||| S:4037 E:4040 ||| VBZ
helpful  ||| S:4040 E:4048 ||| JJ
in  ||| S:4048 E:4051 ||| IN
assessment  ||| S:4051 E:4062 ||| NN
of  ||| S:4062 E:4065 ||| IN
severity  ||| S:4065 E:4074 ||| NN
and  ||| S:4074 E:4078 ||| CC
prognosis  ||| S:4078 E:4088 ||| NN
of  ||| S:4088 E:4091 ||| IN
sepsis ||| S:4091 E:4097 ||| NN
;  ||| S:4097 E:4099 ||| :
it  ||| S:4099 E:4102 ||| PRP
also  ||| S:4102 E:4107 ||| RB
has  ||| S:4107 E:4111 ||| VBZ
a  ||| S:4111 E:4113 ||| DT
certain  ||| S:4113 E:4121 ||| JJ
clinical  ||| S:4121 E:4130 ||| JJ
value  ||| S:4130 E:4136 ||| NN
in  ||| S:4136 E:4139 ||| IN
the  ||| S:4139 E:4143 ||| DT
assessment  ||| S:4143 E:4154 ||| NN
of  ||| S:4154 E:4157 ||| IN
sepsis  ||| S:4157 E:4164 ||| JJ
cardiovascular  ||| S:4164 E:4179 ||| JJ
function  ||| S:4179 E:4188 ||| NN
damage ||| S:4188 E:4194 ||| NN
.  ||| S:4194 E:4196 ||| .
